The probability of developing NPC is 6.7–41.9 times higher for subjects seropositive for immunoglobulin A antibodies against viral capsid antigen (VCA/IgA) than those with undetectable antibodies [2]. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.